The invention provides modulators for the orphan nuclear receptor ROR³ and methods for treating ROR³ mediated diseases by administering these novel ROR³ modulators to a human or a mammal in need thereof. Specifically, the present invention relates to compounds for use ROR³ modulators, wherein the compounds are carboxamide containing cyclic compounds of Formula ( 6 ) to Formula ( 9 ) and the enantiomers, diastereomers, tautomers, N-oxides, solvates and pharmaceutically acceptable salts thereof.
